C.H. Robinson Worldwide (CHRW) reported $4.14 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 7.7%. EPS of $1.29 for the same period compares to $1.15 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $4.22 billion, representing a surprise of -1.98%. The company delivered an EPS surprise of +10.26%, with the consensus EPS estimate being $1.17. While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...

Core Insights - Northwest Bancshares (NWBI) reported a revenue of $150.38 million for the quarter ended June 2025, reflecting a year-over-year increase of 53.5% [1] - The earnings per share (EPS) for the quarter was $0.30, up from $0.27 in the same quarter last year, with an EPS surprise of +3.45% compared to the consensus estimate of $0.29 [1] - The reported revenue exceeded the Zacks Consensus Estimate by +1.61% [1] Financial Performance Metrics - The efficiency ratio for Northwest Bancshares was reported at 64.9%, higher than the average estimate of 62.9% based on two analysts [4] - The net interest margin was 3.6%, slightly above the estimated 3.5% by two analysts [4] - The average balance of total interest-earning assets was $13.54 billion, compared to the estimated $13.59 billion [4] - Mortgage banking income was $1.08 million, exceeding the average estimate of $0.85 million [4] - Total noninterest income was reported at $30.94 million, surpassing the average estimate of $30.35 million [4] Stock Performance - Shares of Northwest Bancshares have returned -0.8% over the past month, while the Zacks S&P 500 composite increased by +3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Middlefield Banc Corp. (MBCN) reported a revenue of $20.52 million for the quarter ended June 2025, reflecting a year-over-year increase of 21.8% [1] - The earnings per share (EPS) for the same quarter was $0.76, up from $0.52 in the previous year [1] - The reported revenue exceeded the Zacks Consensus Estimate by 10.3%, while the EPS surprise was 33.33% above the consensus estimate [1] Financial Performance Metrics - The efficiency ratio was reported at 64.5%, better than the average estimate of 67.5% from two analysts [4] - The net interest margin stood at 3.9%, surpassing the average estimate of 3.7% [4] - Average interest-earning assets were $1.83 billion, slightly above the estimated $1.8 billion [4] - Total noninterest income was $3.08 million, significantly higher than the estimated $1.85 million [4] - Net interest income reached $17.44 million, exceeding the average estimate of $16.75 million [4] Stock Performance - Over the past month, shares of Middlefield Banc have returned +0.9%, compared to a +5.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - Amphastar Pharmaceuticals reported revenue of $170.53 million for the quarter ended March 2025, reflecting a year-over-year decline of 0.8% [1] - The earnings per share (EPS) for the same period was $0.74, down from $1.04 a year ago, with a surprise of +12.12% compared to the consensus estimate of $0.66 [1] - The reported revenue was a surprise of -0.69% against the Zacks Consensus Estimate of $171.71 million [1] Revenue Breakdown - Primatene MIST generated net revenues of $29.05 million, exceeding the average estimate of $27.64 million, representing a year-over-year increase of +20.2% [4] - Glucagon reported net revenues of $20.84 million, slightly above the estimated $20.24 million, but showed a year-over-year decline of -27% [4] - Lidocaine achieved net revenues of $13.64 million, surpassing the average estimate of $13.15 million, with a year-over-year increase of +6.8% [4] - Epinephrine's net revenues were $18.59 million, above the estimated $18.21 million, but reflected a significant year-over-year decline of -28.8% [4] Stock Performance - Amphastar's shares returned +0.5% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Interparfums reported revenue of $338.82 million for Q1 2025, a year-over-year increase of 4.6% and a surprise of +0.47% over the Zacks Consensus Estimate of $337.22 million [1] - The EPS for the same period was $1.32, compared to $1.27 a year ago, with an EPS surprise of +16.81% against the consensus estimate of $1.13 [1] Revenue Performance by Region - North America: Net sales of $123 million, exceeding the average estimate of $119.03 million, with a year-over-year change of +13.8% [4] - Western Europe: Net sales of $86.20 million, above the average estimate of $74.28 million, reflecting a +1.3% year-over-year change [4] - Eastern Europe: Net sales of $25.60 million, surpassing the average estimate of $20.80 million, with a significant year-over-year increase of +46.3% [4] - Central and South America: Net sales of $31 million, slightly below the average estimate of $31.22 million, showing a year-over-year decline of -9.9% [4] - Middle East and Africa: Net sales of $22.70 million, below the average estimate of $29.97 million, with a year-over-year decrease of -16.2% [4] - Asia/Pacific: Net sales of $50.30 million, compared to the average estimate of $56.36 million, reflecting a -2.9% year-over-year change [4] - Europe: Total net sales of $247.80 million, exceeding the average estimate of $242.70 million, with a year-over-year increase of +7.3% [4] - United States: Net sales of $94.30 million, below the average estimate of $96.76 million, indicating a -1.5% year-over-year change [4] Stock Performance - Interparfums shares have returned +8.6% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - ResMed reported $1.29 billion in revenue for the quarter ended March 2025, a year-over-year increase of 7.9% and an EPS of $2.37 compared to $2.13 a year ago, exceeding the Zacks Consensus Estimate of $1.28 billion by 0.53% [1] Financial Performance - The company delivered an EPS surprise of 0.42%, with the consensus EPS estimate being $2.36 [1] - Shares of ResMed have returned -3.3% over the past month, while the Zacks S&P 500 composite changed by -6.6% [3] Regional Performance - U.S., Canada, and Latin America - Devices: $422.70 million, a change of +5.9% year over year, compared to the average estimate of $426.47 million [4] - U.S., Canada, and Latin America - Masks and other: $326.70 million, representing a +13.4% change year over year, exceeding the estimate of $318.76 million [4] - Combined Europe, Asia, and other markets - Total: $381.30 million, a +5.5% change year over year, compared to the estimate of $377.86 million [4] - Combined Europe, Asia, and other markets - Devices: $253.50 million, a +6.1% change year over year, exceeding the estimate of $249.75 million [4] - Combined Europe, Asia, and other markets - Masks and other: $127.70 million, a +4.2% change year over year, slightly below the estimate of $128.11 million [4] - U.S., Canada, and Latin America - Total: $749.30 million, a +9% change year over year, compared to the estimate of $745.22 million [4] Global Revenue Breakdown - Global revenue - Total Sleep and Breathing Health: $1.13 billion, a +7.8% change year over year, exceeding the estimate of $1.12 billion [4] - Global revenue - Residential Care Software: $161.20 million, a +8.9% change year over year, slightly above the estimate of $161.15 million [4] - Global revenue - Total Devices: $676.20 million, a +6% change year over year, in line with the estimate of $676.22 million [4] - Global revenue - Total Masks and other: $454.40 million, a +10.6% change year over year, exceeding the estimate of $446.86 million [4]